相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Revisiting the role of CD4+T cells in cancer immunotherapy-new insights into old paradigms
Rong En Tay et al.
CANCER GENE THERAPY (2021)
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
Christopher S. Garris et al.
CLINICAL CANCER RESEARCH (2020)
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Maud Mayoux et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
Chuanhui Han et al.
NATURE IMMUNOLOGY (2020)
Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity
Ilgen Mender et al.
CANCER CELL (2020)
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Ugur Sahin et al.
NATURE (2020)
cDC1 prime and are licensed by CD4+T cells to induce anti-tumour immunity
Stephen T. Ferris et al.
NATURE (2020)
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Qi Peng et al.
NATURE COMMUNICATIONS (2020)
A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results
D. P. Zandberg et al.
ANNALS OF ONCOLOGY (2020)
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer
Soyoung A. Oh et al.
NATURE CANCER (2020)
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Interferons α and β in cancer: therapeutic opportunities from new insights
Ernest C. Borden
NATURE REVIEWS DRUG DISCOVERY (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot et al.
CELL RESEARCH (2019)
Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation
Jianzhou Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
Anje Cauwels et al.
ONCOIMMUNOLOGY (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells
Paul A. Beavis et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
M. Thomas et al.
ANNALS OF ONCOLOGY (2018)
Interferon-α Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling
Alexandr V. Bazhin et al.
FRONTIERS IN IMMUNOLOGY (2018)
LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
K J Harrington et al.
ANNALS OF ONCOLOGY (2018)
Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response
Assaf Marcus et al.
IMMUNITY (2018)
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Derek J. Theisen et al.
SCIENCE (2018)
Targeting IFN alpha to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
Yong Liang et al.
NATURE COMMUNICATIONS (2018)
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Jan P. Boettcher et al.
TRENDS IN CANCER (2018)
Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Anje Cauwels et al.
CANCER RESEARCH (2018)
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression
Zhenhua Ren et al.
CLINICAL CANCER RESEARCH (2017)
Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study
Renata Ursu et al.
EUROPEAN JOURNAL OF CANCER (2017)
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling
Meng Michelle Xu et al.
IMMUNITY (2017)
cGAS surveillance of micronuclei links genome instability to innate immunity
Karen J. Mackenzie et al.
NATURE (2017)
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Shane M. Harding et al.
NATURE (2017)
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence
Selene Gluck et al.
NATURE CELL BIOLOGY (2017)
cGAS is essential for the antitumor effect of immune checkpoint blockade
Hua Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
A. R. Sanchez-Paulete et al.
ANNALS OF ONCOLOGY (2017)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy
Stefani Spranger et al.
CANCER CELL (2017)
From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy
Liufu Deng et al.
CLINICAL CANCER RESEARCH (2016)
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Alfonso R. Sanchez-Paulete et al.
CANCER DISCOVERY (2016)
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Joseph L. Benci et al.
CELL (2016)
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
Helene Salmon et al.
IMMUNITY (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz et al.
NATURE (2016)
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Meng Michelle Xu et al.
TRENDS IN IMMUNOLOGY (2016)
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours
Martin R. Weihrauch et al.
EUROPEAN JOURNAL OF CANCER (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Induction of Telomere Dysfunction Mediated by the Telomerase Substrate Precursor 6-Thio-2'-Deoxyguanosine
Ilgen Mender et al.
CANCER DISCOVERY (2015)
Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity (vol 26, pg 638, 2014)
Miranda L. Broz et al.
CANCER CELL (2014)
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Xuanming Yang et al.
CANCER CELL (2014)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors
Lisa L. R. Hartman et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu et al.
NATURE MEDICINE (2014)
The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting
Miriam Merad et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Control of T Helper 2 Responses by Transcription Factor IRF4-Dependent Dendritic Cells
Yan Gao et al.
IMMUNITY (2013)
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Jiaxi Wu et al.
SCIENCE (2013)
Anti-CD20 Antibody Therapy for B-Cell Lymphomas
David G. Maloney
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Plasmacytoid dendritic cells and their therapeutic activity in cancer
Aldo Pinto et al.
ONCOIMMUNOLOGY (2012)
Trial watch FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
Byron C. Burnette et al.
CANCER RESEARCH (2011)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs et al.
CLINICAL CANCER RESEARCH (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Type I IFNs Control Antigen Retention and Survival of CD8α+ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming
Silvia Lorenzi et al.
JOURNAL OF IMMUNOLOGY (2011)
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
John Stagg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
SaeGwang Park et al.
CANCER CELL (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors
Elizabeth D. Thompson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)
Nicholas Butowski et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Hiroki Ishikawa et al.
NATURE (2009)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
Kai Hildner et al.
SCIENCE (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis
Marcus Muehlbauer et al.
JOURNAL OF HEPATOLOGY (2006)
NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells
Ariel Savina et al.
CELL (2006)
Side effects of interferon-α therapy
S Sleijfer et al.
PHARMACY WORLD & SCIENCE (2005)
A critical function for type I interferons in cancer immunoediting
GP Dunn et al.
NATURE IMMUNOLOGY (2005)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Interferons, interferon-like cytokines, and their receptors
S Pestka et al.
IMMUNOLOGICAL REVIEWS (2004)
Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation:: relevance for the immune modulatory effect in multiple sclerosis
B Schreiner et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
